<div id="readability-page-1"><p>Orchard Capital Management LLC cut its holdings in  Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 57.3% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 79,208 shares of the company's stock after selling 106,288 shares during the period. Intellia Therapeutics comprises approximately  0.8% of Orchard Capital Management LLC's holdings, making the stock its 29th biggest position. Orchard Capital Management LLC owned 0.08% of Intellia Therapeutics worth $743,000 as of its most recent SEC filing.</p><ul><li>Goldman Spotlights These 3 Stocks in Its Bullish S&amp;P 500 Outlook</li></ul><p>A number of other institutional investors have also modified their holdings of NTLA. Vanguard Group Inc. raised its stake in  Intellia Therapeutics by 5.5% during the first quarter. Vanguard Group Inc. now owns 10,752,031 shares of the company's stock worth $76,447,000 after acquiring an additional 561,978 shares during the period.  Geode Capital Management LLC grew its holdings in shares of  Intellia Therapeutics by 5.1% during the second quarter. Geode Capital Management LLC now owns 2,606,222 shares of the company's stock valued at $24,449,000 after purchasing an additional 126,049 shares during the last quarter.  JPMorgan Chase &amp; Co. grew its holdings in shares of  Intellia Therapeutics by 73.0% during the second quarter. JPMorgan Chase &amp; Co. now owns 940,483 shares of the company's stock valued at $8,822,000 after purchasing an additional 396,858 shares during the last quarter.  Vestmark Advisory Solutions Inc. raised its position in shares of  Intellia Therapeutics by 104.7% during the 2nd quarter. Vestmark Advisory Solutions Inc. now owns 638,342 shares of the company's stock worth $5,988,000 after purchasing an additional 326,460 shares during the period.  Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of  Intellia Therapeutics by 8.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 521,706 shares of the company's stock worth $3,709,000 after purchasing an additional 38,521 shares during the last quarter. Institutional investors own  88.77% of the company's stock. </p><div><p><span></span><span>Get <strong>Intellia Therapeutics</strong> alerts:</span></p></div><h2>Intellia Therapeutics Stock Down 0.4%</h2><p>NTLA opened at $8.52 on Friday. The firm has a market cap of $986.87 million, a PE ratio of -2.00 and a beta of 2.44. The business has a fifty day simple moving average of $16.26 and a 200-day simple moving average of $12.52. Intellia Therapeutics, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $28.25. </p><ul><li>Analysts Think These Stocks Could More Than Double in Value</li></ul><p>Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its earnings results on Thursday, November 6th. The company reported ($0.92) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.02) by $0.10. Intellia Therapeutics had a negative return on equity of 57.01% and a negative net margin of 774.94%.The company had revenue of $13.78 million for the quarter, compared to analyst estimates of $14.12 million. During the same period in the previous year, the firm earned ($1.34) earnings per share. Intellia Therapeutics's revenue for the quarter was up 51.6% compared to the same quarter last year.  On average, equities research analysts anticipate that  Intellia Therapeutics, Inc. will post -5.07 EPS for the current fiscal year. </p><h2>Analyst Ratings Changes</h2><p>A number of research analysts recently commented on NTLA shares. HC Wainwright lowered their price objective on Intellia Therapeutics from $18.00 to $15.00 and set a &#34;buy&#34; rating for the company in a research note on Monday, November 10th. Chardan Capital reduced their price target on shares of Intellia Therapeutics from $48.00 to $26.00 and set a &#34;buy&#34; rating for the company in a report on Friday, November 7th. Truist Financial  restated a &#34;buy&#34; rating and set a $14.00 price target (down previously from $25.00) on shares of Intellia Therapeutics in a research report on Monday, November 10th. Citigroup  reaffirmed a &#34;market outperform&#34; rating on shares of Intellia Therapeutics in a report on Tuesday, October 28th. Finally, Evercore ISI  set a $8.00 target price on shares of Intellia Therapeutics and gave the company an &#34;in-line&#34; rating in a research note on Tuesday, November 11th. Eleven research analysts have rated the stock with a Buy rating, ten have assigned  a Hold rating and three have issued  a Sell rating to the company's stock. Based on data from MarketBeat, Intellia Therapeutics  has a consensus rating of &#34;Hold&#34; and a consensus target price of $18.43.</p><ul><li>2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025</li></ul><p><b>View Our Latest Report on NTLA</b></p><h2>Insider Transactions at Intellia Therapeutics</h2><p>In other Intellia Therapeutics news, CAO Michael P. Dube sold 1,871 shares of the company's stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $17.38, for a total transaction of $32,517.98. Following the completion of the sale, the chief accounting officer directly owned 55,266 shares of the company's stock, valued at approximately $960,523.08. This represents a 3.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. Insiders own  3.10% of the company's stock. </p><h2>Intellia Therapeutics Profile</h2> (Free Report)<p>Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Intellia Therapeutics</li><li>3 Defense Stocks Set to Benefit From Increased Military Spending</li><li>How Semtech’s Data Center Chips Are Powering the AI Boom</li><li>ETF Screener: Uses and Step-by-Step Guide </li><li>Keysight Technologies' Surge: The Market Wakes Up to This AI Play</li><li>P/E Ratio Calculation: How to Assess Stocks</li><li>Is American Express the Credit Stock For a K-Shaped Economy?</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlRMQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlRMQQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Intellia Therapeutics Right Now?</h2><p>Before you consider Intellia Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list.</p><p>While Intellia Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

NTLA

<p>Orchard Capital Management LLC reduced its stake in Intellia Therapeutics by 57.3% in Q2, selling 106,288 shares. Intellia's stock is now its 29th largest position, comprising 0.8% of its holdings. Other institutional investors have adjusted their positions in NTLA. Intellia's stock opened at $8.52, with a market cap of $986.87 million. Analysts have mixed ratings, with a consensus target price of $18.43. Intellia's Q3 revenue rose 51.6% year-over-year, with EPS beating estimates.</p>

Intellia Therapeutics, Inc. $NTLA Shares Sold by Orchard Capital Management LLC